Petroleum jelly
PreclinicalSmall molecule
Johnson & JohnsonPetroleum jelly is one of 11 small molecule programs targeting Seborrheic Dermatitis. It is currently in Preclinical.
1
Indications
4
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Seborrheic Dermatitis
#DrugCompanyPhaseTrials
1Jakafi
IncyteApproved
Daliresp
AstraZenecaApproved
Prograf
VVeloxis Pharmaceuticals
Approved
Elidel
BBausch Health Americas, Inc.
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Rayos
RRoxane Laboratories
Approved
Eucrisa
AAnacor
Approved
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Seborrheic Dermatitis1 trial
Irritation1 trial
Staphylococcus Aureus1 trial
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
Completed·—·Phase 2·NCT02967432·216 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Petroleum jelly. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company